|Bid||2.08 x 0|
|Ask||2.09 x 0|
|Day's Range||2.06 - 2.20|
|52 Week Range||0.47 - 4.70|
|Beta (3Y Monthly)||4.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“ or the “Company“), and Serruya Private Equity (“Serruya” and together with the Company, the “Parties”), have settled final forms of definitive joint venture and other agreements that will see the Parties launch a Canada-wide cannabis retail Joint Venture (“Retail JV”) along with a domestic and international cannabis brands Joint-Venture (“Brands JV”, and together with the Retail JV, the “Joint Venture”). Serruya will also make a $10 million strategic investment in Aleafia via a non-brokered private placement financing (“Private Placement”) and Aleafia will invest $5 million of such gross proceeds of the Private Placement into the Joint Venture.
Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia”) has entered into a global agreement with D2L (Desire2Learn) Corporation ("D2L"), in which Aleafia Health will deploy D2L's Learning Management System (LMS) Brightspace. Brightspace is a cloud-based learning platform employed by major organizations including Walmart, the American Nurses Association and the Elementary Teachers’ Federation of Ontario.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), a highly differentiated cannabis company with major cannabis cultivation and medical clinic operations, will release its financial results and hold its Third Quarter Results Call on November 26, 2018. Neither Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“) is announcing that it will hold a special meeting (the “Meeting”) of shareholders on Thursday, December 6, 2018 at 9:00 a.m. (Toronto time) at Famee Furlane Club – Friuli Hall, 7065 Islington Avenue, Woodbridge, ON. “Listing on the NASDAQ is another step as we continue the relentless execution of our stated goal of attaining a global leadership position in the cannabis space," said Aleafia Chairman Julian Fantino. "Asking shareholders to approve a range for a possible share consolidation will provide management the flexibility to adjust the number of shares, but only if necessary, to achieve the minimum bid price requirements to complete our NASDAQ listing process," said Aleafia CEO Geoffrey Benic.
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / National support for marijuana legalization continues to grow as around two-thirds of the US supports legalization. Integrated Cannabis plans to begin distributing CBD-based gummies through its contract manufacturer, Titration Technologies, in Phoenix, Arizona.
VANCOUVER , Nov. 5, 2018 /CNW/ - Trading resumes in: Company: Aleafia Health Inc. TSX-Venture Symbol: ALEF Resumption (ET): 10:04:01 AM IIROC can make a decision to impose a temporary suspension (halt) ...
VANCOUVER , Nov. 5, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Aleafia Health Inc. TSX-Venture Symbol: ALEF Reason: Single Stock Circuit Breaker Halt Time (ET): 9:59:01.302 AM ...
Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) and CannaPacific Pty Ltd. (“CannaPacific”), together the (“Parties”), have signed a non-binding term sheet in which, upon completion of the transaction, Aleafia will acquire a 10 per cent equity stake in CannaPacific. CannaPacific is a Licensed Australian Medical Cannabis company based in Newcastle and the Macleay Valley on the mid-north coast of NSW, Australia. As at the date of this Term Sheet, CannaPacific has been granted licences to cultivate, produce and research medical cannabis in Australia and has a 53,000 sq. ft. cannabis cultivation and plant research facility currently under construction.
Aleafia Labs, a division of Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) and Guided 420 Genetics Inc. (“G420”) with U.S.-based AKESOgen, Inc., (“AKESOgen”), together the (“Parties”), are announcing the commencement of a joint study (“the Study”) on cannabinoid pharmacogenetics in medical cannabis therapy. The initial 200 patient study will focus on developing medical cannabis patient genetic screening tools in the areas of THC-CBD sensitivity and metabolism, Endocannabinoid Deficiency Syndrome and cannabis treatment safety and adverse event risk. This initiative will be funded by G420 and will be administered by Aleafia physicians practicing within the Canabo Medical Clinic network.
Investing.com - The once-hot Cannabis sector extended its losses in the wake of its worst week in nine months, weighed down by a slump in Aurora Cannabis.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), a highly differentiated cannabis company with major cannabis cultivation and medical clinic operations is formally launching a research, development and innovation division to be called Aleafia Labs (“Aleafia Labs”). Aleafia Labs will leverage the company’s existing patient database and intellectual property to advance the development of proprietary cannabis products.
Major Adult-Use Retail, Brand JV Backed by Family Behind Iconic Yogen Früz, Second Cup Brands TORONTO, Oct. 26, 2018 -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA:.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one of Canada’s leading, vertically integrated cannabis companies, has made a significant expansion of its medical clinic business, adding three new clinics, six new physicians and a major expansion of telemedicine services for patients. Aleafia will also add nurse practitioners (NP) to complement physician-led treatment and to meet a significant increase in patient demand. The expansion of telemedicine service is part of a broader management strategy of treating a greater number of patients at reduced cost.
The JV marks the first phase of a multiphase strategy that will see Aleafia enter the adult-use cannabis industry and related retail operations in Canada and globally. This will create the foundation for the adult-use business pillar, joining Aleafia’s two existing business pillars - cannabis cultivation and medical clinic operations.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia”) or (the “Company”), one of Canada’s leading, vertically integrated cannabis companies, is announcing that it will move forward with an industry first secure, low-cost outdoor cannabis grow. The company has now obtained local regulatory approval for a 60,000 kg capacity expansion at its Port Perry cultivation facility. Pending standard Health Canada approvals, Aleafia will build an innovative, secure outdoor cultivation site, leading to significant reduction in up front capital investments, operating expenses and ultimately, a lower cost per gram output.
TORONTO, Oct. 03, 2018 -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one of Canada’s leading, vertically integrated cannabis.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one of Canada’s leading, vertically integrated cannabis companies, is announcing that it has submitted a finalized application to list its common shares on the NASDAQ. Listing on a major United States stock exchange will provide unparalleled liquidity and place Aleafia among a small handful of Canadian cannabis companies. The U.S. based NASDAQ stock market is the second largest stock exchange by market capitalization.
Aleafia Health Inc. (TSXV: ALEF, OTCQX: ALEAF, FRA: ARAH) (the "Company" or "Aleafia") announces a proposed early exercise warrant program (the "Program") designed to encourage the early exercise of up to 12,085,500 warrants with an exercise price of $1.75 per warrant and an expiration date of September 27, 2019 (the "Warrants"). The Program will be open to eligible Canadian holders of the Warrants who exercise during a 30 day period expected to commence as soon as possible following receipt of TSX Venture Exchange conditional approval (the "Early Exercise Period"). Upon receipt of such approval, the Company will issue a further press release announcing the commencement date of the Early Exercise Period.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), has signed a supply MOU (“the MOU”) with CannTrust Holdings Inc. (TRST.TO) (“CannTrust”). Under the terms of the agreement, CannTrust has the right to purchase up to 15,000 kg of cannabis from Aleafia in 2019. The MOU follows Aleafia obtaining its Sales Licence this month.
OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), has entered into a letter of intent to acquire a 51 per cent stake in One Plant™, an adult-use cannabis retail operation led by members of the Serruya Family (the “Serruya Family”), including Aaron Serruya, the president of International Franchise Inc., which has over 4500 franchise locations in over 50 countries. Serruya Family has also been a leading force in the cannabis industry as early investors of Aphria (“TSX:APH”) and the majority shareholder of Liberty Health Sciences (“CNSX: LHS”).
HMMJ is the world's first and largest Exchange Traded Fund (ETF) offering direct exposure to North American publicly listed life sciences companies with significant business activities in the marijuana industry.